Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article provides a critical overview of recent discoveries in the genetics and molecular processes involved in androgenetic alopecia, focusing on its polygenic basis and DHT dependency, but reports no new clinical results.

This study found that the peach gene CTG134 mediates auxin-ethylene crosstalk, affecting root hair growth and hormone-regulated processes in plants.

This study found that the yeast androgen screen (YAS) could detect the activity of methyltestosterone in urine for a longer period than classical GC/MS, potentially identifying long-lasting metabolites.

This study found that TSG-enriched Polygonum multiflorum extract, optimized through microwave-assisted and chromatographic methods, promotes hair regrowth in a mouse model of androgenetic alopecia via 5α-reductase inhibition and Wnt/β-catenin pathway activation, suggesting its potential as a natural treatment.

This study proposes a new treatment protocol combining autologous regenerative therapy with mesotherapy and photobiostimulation for androgenetic alopecia, leveraging adipose-derived stem cells to stimulate hair follicle regeneration.

This study found that the Transdermal Delivery System efficiently delivers testosterone systemically and showed bioequivalent hormone concentrations to a known topical gel in healthy males.

Coffee and tea might help hair growth in balding individuals, but side effects and alternative uses are being considered.

This study found that WD-aptamer increased β-catenin expression and promoted human hair follicle dermal papilla cell proliferation by interfering with the CXXC5-Dvl1 interaction in the Wnt signaling pathway.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

This study found that DGAT1 functions as a key enzyme in murine skin to regulate retinoic acid levels and prevent retinoid toxicity, impacting hair cycle and sensitivity to retinol.

Researchers found an RNA transcript that might help control a growth factor linked to tumor development.

This study aims to evaluate the prevalence of androgenetic alopecia in transgender men undergoing testosterone therapy, noting that such hormone treatment can lead to dermatological issues that significantly affect their quality of life. Results are not reported in the abstract.

This study concluded that ACT injections, alone or combined with finasteride, have significant therapeutic effects and safety in treating androgenic alopecia, with promising clinical potential.

In this study, researchers tested a tea leaf ethanol extract (Camellia sinensis) hair tonic and found it increased average hair growth compared to positive and negative controls over 28 days, but exhibited some instability and inhomogeneity after accelerated testing.

This study found that increased expression of type 2 TGF-β and type II receptor was observed in the bald vertex area of hair follicles from androgenetic alopecia patients, suggesting a role in catagen induction.

This study reports the development of the first rodent model for androgenetic alopecia, demonstrating that overexpression of androgen receptors in mice delays hair regeneration and can be used to test new treatments.

This review highlights that while finasteride and minoxidil effectively treat androgenetic alopecia, emerging options like dutasteride, mesotherapy, androgen blockers, and red LED therapy show promising results, especially when used in combination, though further research is needed for standardization and safety confirmation.

In this case report, a 28-year-old male with androgenetic alopecia showed improved hair density and shaft thickness after four monthly sessions of autologous growth factor concentrate injections, with no adverse effects and high patient satisfaction, suggesting the treatment’s promise as a safe and effective option.

This study found that Agaricus bisporus-derived β-Glucan particles showed potential as an anticancer, antimicrobial, and antioxidant agent, inducing apoptosis and disrupting mitochondrial membrane potential in cervical cancer HeLa cells.

This study found that hamster sebaceous glands have high affinity binding sites for dihydrotestosterone, with competition from other steroids indicating specific binding characteristics.

This review discusses Amphiregulin (AREG) as a potential target for treating fibrotic disorders and cancer, highlighting its role in disease progression and promising results in preclinical studies and early trials.

In this study, the addition of a topical gel containing growth-factor mimicking oligopeptides and other ingredients showed improved efficacy in subjects with androgenic alopecia using minoxidil or finasteride compared to drug treatment alone.

This source reports that trastuzumab deruxtecan improves outcomes in HER2-positive and HER2-low metastatic breast cancer, emphasizing the need for careful adverse event monitoring, particularly for interstitial lung disease, and managing emetic risk to maximize benefits.

In this study, intradermal injection of botulinum toxin was associated with increased hair growth in men with androgenetic alopecia through the suppression of TGF-β1 secretion from dermal papilla cells.

Prostaglandin D2, found in higher levels in bald scalps, stops hair growth and could be a target for treating hair loss.

This review discusses the potential role of thyroid receptor β agonists in treating androgenetic alopecia, reporting no new clinical results while highlighting their mechanism and anti-alopecia efficacy.

This study found that incorporating CTA2-BADG, a modified hair-rebonding compound, into damaged hair significantly improved surface morphology and tensile strength by using charge-conversion chemistry to enhance penetration into the hair shaft.

The authors concluded that finasteride should be preferred over dutasteride for treating male androgenetic alopecia, as it better preserves certain important functions.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.